Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C24H22Cl2N4O5 |
| Molecular Weight | 517.361 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(Cl)=C(C=C1)[C@@]3(CN2C=CN=C2)OC[C@H](COC4=CC=C(C=C4)N5CCNC(=O)C5=O)O3
InChI
InChIKey=HQSHCFXABCJJOF-CYFREDJKSA-N
InChI=1S/C24H22Cl2N4O5/c25-16-1-6-20(21(26)11-16)24(14-29-9-7-27-15-29)34-13-19(35-24)12-33-18-4-2-17(3-5-18)30-10-8-28-22(31)23(30)32/h1-7,9,11,15,19H,8,10,12-14H2,(H,28,31)/t19-,24-/m0/s1
| Molecular Formula | C24H22Cl2N4O5 |
| Molecular Weight | 517.361 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 13:37:14 UTC 2023
by
admin
on
Sat Dec 16 13:37:14 UTC 2023
|
| Record UNII |
ZF74VO947S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ZF74VO947S
Created by
admin on Sat Dec 16 13:37:14 UTC 2023 , Edited by admin on Sat Dec 16 13:37:14 UTC 2023
|
PRIMARY | |||
|
101671865
Created by
admin on Sat Dec 16 13:37:14 UTC 2023 , Edited by admin on Sat Dec 16 13:37:14 UTC 2023
|
PRIMARY | |||
|
159898-58-5
Created by
admin on Sat Dec 16 13:37:14 UTC 2023 , Edited by admin on Sat Dec 16 13:37:14 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
Evidence that CYP3A4 plays a significant role in metabolism of ketoconazole is that co-administration of CYP3A4 inducers, such as phenytoin, carbamazepine, and rifampin, can cause as much as a 50% reduction in levels of ketoconazole.
MAY BE CLINICALLY SIGNIFICANT
|
